Genetic polymorphisms associated with cyclophosphamide outcome and risk of toxicity in patients with lupus nephritis

Indrawijaya, Yen Yen Ari, Hamijoyo, Laniyati, Artarini, Aluicia Anita and Iwo, Maria Immaculata (2023) Genetic polymorphisms associated with cyclophosphamide outcome and risk of toxicity in patients with lupus nephritis. Acta Medica Indonesiana, 55 (3). pp. 343-349. ISSN 2338-2732

Preview

Text 17936.pdf - Published Version Available under License Creative Commons Attribution. Download (600kB) | Preview

Abstract

A 6-month cyclophosphamide induction therapy followed by maintenance therapy every three months is the first-line treatment for Class III, IV, and V lupus nephritis. Among the 139 single nucleotide polymorphisms (SNPs) associated with cyclophosphamide, four SNPs, namely rs4244285, rs4802101, rs7254579 and rs3957356, are related to the response and risk of toxicity in patients with lupus nephritis. Although pharmacogenetic studies in patients with lupus nephritis (LN) have not been conducted previously in Indonesia, data on rs4244285 are available for several ethnic groups, including Papuans, Bataks, Balinese, Dayaks, Javanese, Bugis, Chinese, Timorese and Malays, even though direct evidence in LN patients is less detectable. However, this can be followed up prior to cyclophosphamide therapy based on the identification of genetic markers. Therefore, clinical studies in patients with lupus nephritis are deemed necessary to evaluate the potential of these markers.

Item Type:	Journal Article
Keywords:	Cyclophosphamide; SNP; response; risk of toxicity
Subjects:	11 MEDICAL AND HEALTH SCIENCES > 1115 Pharmacology and Pharmaceutical Sciences > 111505 Pharmacogenomics
Divisions:	Faculty of Medical and Health Sciences > Department of Pharmacy
Depositing User:	Yen Yen Indrawijaya
Date Deposited:	12 Jan 2024 09:29

Downloads

Origin of downloads

Actions (login required)

View Item